Winshine Science Co., Ltd. (0209) AI Stock Analysis

• Market Cap: HK$27.08M
• Dividend Yield: N/A
• Average Volume (3M): 47.66K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.18
• Revenue Growth: -1.41%
• EPS Growth: -63.88%
• Country: HK
• Employees: 1,654
• Sector: Consumer Cyclical
• Sector Strength: 65
• Industry: Leisure
• EPS (TTM): -0.32
• Shares Outstanding: 154,757,480
• 10 Day Avg. Volume: 32,536
• 30 Day Avg. Volume: 47,664
• PEG Ratio: <0.01
• Price to Book (P/B): -0.17
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 30 Underperform
• Price Target: ―

Winshine Science Co., Ltd. is underperforming due to significant financial instability, reflected in negative equity and cash flow issues. Technical analysis supports a bearish trend, and poor valuation metrics further impact the stock's appeal.

Winshine Science Co., Ltd. Business Overview & Revenue Model

Company Description

Winshine Science Company Limited, an investment holding company, manufactures and trades in hard and stuffed toys in Hong Kong, the People's Republic of China, the United States, Europe, and Korea. The company operates in three segments: Securities Investments, Toys, and Medical and Health. It engages in the securities investment and trading activities; provision of credit finance and management services; property leasing activities; and research and development of medical and health technology solutions. The company was formerly known as Winshine Entertainment & Media Holding Company Limited and changed its name to Winshine Science Company Limited in February 2016. The company was incorporated in 2001 and is headquartered in Admiralty, Hong Kong.

How the Company Makes Money

Winshine Science Co., Ltd. generates revenue through multiple streams, primarily focusing on the sale of pharmaceutical products and medical devices. The company invests heavily in research and development to create innovative products that meet market demands, thereby driving sales growth. In addition to product sales, Winshine Science may engage in strategic partnerships and collaborations with other companies in the healthcare sector to expand its market reach and leverage shared expertise. These partnerships can include joint ventures, licensing agreements, and distribution deals, which contribute to the company's revenue. Furthermore, the company may also explore opportunities in emerging markets and expand its product offerings to enhance its financial performance.

Winshine Science Co., Ltd. Financial Statement Overview

Summary

Winshine Science Co., Ltd. is facing significant financial challenges with declining revenue, negative profitability, negative equity, and cash flow issues. High debt levels further add to the financial risk.

Income Statement

Winshine Science Co., Ltd. shows a declining revenue trend with a significant drop in revenue from 2020 to 2024. The gross profit margin has deteriorated over the years, indicating declining profitability. Net income has remained negative, highlighting ongoing losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

The company has a negative stockholders' equity, indicating financial instability. The debt-to-equity ratio cannot be calculated due to negative equity, but high total debt suggests leverage risk. The equity ratio is negative, emphasizing a weak financial position.

Cash Flow

The operating cash flow to net income ratio is indeterminate due to zero operating cash flow in 2024, indicating cash flow challenges. Historical cash flow metrics reveal instability with periods of negative free cash flow, complicating growth prospects.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	515.91M	523.26M	849.10M	724.63M	364.31M
Gross Profit	12.80M	39.27M	97.88M	37.26M	18.52M
EBITDA	-28.48M	5.74M	36.37M	-95.91M	-73.52M
Net Income	-73.03M	-28.65M	8.08M	-136.01M	-95.78M
Balance Sheet
Total Assets	352.88M	414.32M	340.95M	550.35M	484.69M
Cash, Cash Equivalents and Short-Term Investments	55.26M	119.33M	49.77M	67.82M	61.37M
Total Debt	219.56M	243.96M	195.73M	276.62M	235.80M
Total Liabilities	493.37M	495.19M	430.59M	649.29M	446.79M
Stockholders Equity	-139.04M	-80.06M	-89.65M	-98.94M	37.90M
Cash Flow
Free Cash Flow	0.00	-3.62M	10.96M	-42.29M	-65.39M
Operating Cash Flow	0.00	9.49M	20.77M	-32.75M	-59.62M
Investing Cash Flow	0.00	-12.25M	37.62M	20.95M	3.52M
Financing Cash Flow	0.00	71.93M	-63.31M	20.00M	-35.10M

Winshine Science Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.18
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0209, the sentiment is Positive. The current price of 0.18 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.15, and above the 200-day MA of 0.18, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 97.65 is Negative, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0209.

Winshine Science Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1348	58 Neutral	HK$103.20M	―	-37.89%	―	-53.52%	-12.78%
Sector *	56 Neutral	HK$25.22B	4.10	-2.03%	6.15%	-0.31%	-67.64%
8545	55 Neutral	HK$53.65M	17.27	-1.08%	―	-34.70%	-550.00%
3830	48 Neutral	HK$69.00M	―	-18.04%	―	1.11%	36.36%
6918	39 Underperform	HK$70.58M	―	-19.60%	―	64.02%	42.01%
0209	30 Underperform	HK$27.08M	―		―	-1.41%	-63.88%
0765	―	HK$147.12M	―	-55.75%	―	―	―

Winshine Science Co., Ltd. Corporate Events

Winshine Science Co., Ltd. Announces Annual General Meeting and Share Issuance Resolutions

Winshine Science Co., Ltd. has announced its upcoming annual general meeting scheduled for May 22, 2025, in Hong Kong. The meeting will address ordinary business matters such as the adoption of financial statements, re-election of directors, and re-appointment of auditors. Additionally, the company will discuss resolutions related to the issuance and management of shares, including the authorization for directors to allot and deal with shares within specified limits.

Winshine Science Reports Increased Losses in 2024 Financial Results

Winshine Science Co., Ltd. reported its audited consolidated financial results for the year ended December 31, 2024, showing a decrease in revenue to HK$515,908,000 from HK$523,262,000 in 2023. The company faced a significant increase in losses, with a net loss of HK$73,762,000 compared to HK$29,361,000 in the previous year, attributed to various impairments and increased finance costs, impacting its financial stability and market positioning.

Winshine Science Co., Ltd. Issues Profit Warning with Increased Losses

Winshine Science Co., Ltd. has issued a profit warning, indicating an expected loss of no less than HKD70 million for the year ending December 31, 2024. This represents a significant increase from the previous year’s loss of approximately HKD30 million, primarily due to reduced gross profit in its toys division and increased impairment loss on property, plant, and equipment.

Winshine Science Co., Ltd. Announces Upcoming Board Meeting for Financial Review

Winshine Science Co., Ltd. has announced that a board meeting will be held on March 31, 2025, to approve the audited final results for the year ending December 31, 2024, and to discuss the recommendation of a final dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential dividend distribution, which could impact investor sentiment and market positioning.

Winshine Science Announces Board and Committee Changes

Winshine Science Co., Ltd., a company incorporated in Bermuda, announced the resignation of Mr. Chan Cheuk Ho as an independent non-executive director effective February 28, 2025. This change also affects the composition of the company’s board committees, with Mr. Kwok Kim Hung Eddie and Ms. Wang Yumei taking on new roles in the audit, remuneration, and nomination committees. These shifts are part of the company’s ongoing efforts to maintain effective governance and leadership.

Winshine Science Co., Ltd. Updates Board of Directors

Winshine Science Co., Ltd. has updated its board of directors, which includes a mix of executive, non-executive, and independent non-executive directors. The announcement outlines the roles and functions of each board member, including their participation in various board committees such as the Audit, Remuneration, and Nomination Committees. This update may impact the company’s governance structure and decision-making processes, potentially influencing its strategic direction and stakeholder relations.